Abstract Library

#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing

Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Espinosa Olarte P, Modrego Sanchez A, Riesco Martinez M, Garcia Carbonero R,

Keywords: Esophageal neuroendocrine carcinoma, tumor genome sequencing, immunotherapy, tumor burden, personalized therapy,

#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers

Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zandee W

Authors: Zandee W, Merola E, de Mestier L, Klümpen H, Geboes K,

Keywords: Standard of Care, Multidisciplinary Tumor Board, Quality of Care,

#1915 Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro

Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Krug S

Authors: Krug S, Gress T, Theuerkorn K, Mordhorst J, Michl P,

Keywords: SSA, targeted therapies, SSTR,

#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs

Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Reidy-Lagunes D

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Mirakhur B, Massien C,

Keywords: Lung NETs, lanreotide,

#1427 Uncinatectomy: Rethinking the Surgical Approach for Neuroendocrine and Intraductal Papillary Mucinous Neoplasms of the Pancreas

Introduction: Pancreatic neuroendocrine tumors (pNETs) and intraductal papillary mucinous neoplasms (IPMN) are increasingly recognized pancreatic tumors due to advances in imaging. Standard of care is surgical resection for these tumors is via the appropriate procedure: pancreaticoduodenectomy or enucleation.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Arora A

Authors: Arora A, Scudamore C, Flint J,

Keywords: Pancreatic neuroendocrine tumor, IPMN, uncinatectomy ,